Mizuho lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report. It moderated the near-term ramp and unadjusted peak sales for NKX019, citing the current competitive landscape in autoimmune diseases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
- Nkarta Announces Leadership Change with New CMO
- Nkarta appoints Shawn Rose as CMO, head of R&D
- Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating
- Nkarta, Inc. Reports Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue